TS-IN-8

TS-IN-8 (Compound 4d) (1-80 μM, 24 h) shows strong inhibitory effects on MCF-7 cells (IC₅₀ = 10.11 μM) and A549 cells (IC₅₀ = 22.49 μM), weaker inhibitory effects on HepG2 cells, and low toxicity to normal McCoy cells (IC₅₀ = 115.86 μM)^[1].
TS-IN-8 (1-5 μM, 24 h) induces apoptosis in MCF-7 cells in a dose-dependent manner and causes cell cycle arrest at the G2/M phase^[1].
TS-IN-8 (1-5 μM, 24 h) induces dose-dependent nuclear morphological changes in MCF-7 cells, including chromatin condensation at 1 μM (apoptotic nuclear index 4.12%) and nuclear fragmentation with apoptotic bodies at 5 μM (apoptotic nuclear index 8.97%), significantly increases intracellular reactive oxygen species (ROS) levels, and activates intrinsic apoptosis pathways by regulating apoptosis-related proteins such as bax/bcl-2 ratio and Caspase activation^[1].
TS-IN-8 (1-5 μM, 6 h) significantly reduces TS protein expression in MCF cells^[1].
TS-IN-8 (1-5 μM, 24 h) inhibits MCF-7 cell migration in a dose-dependent manner^[1].
TS-IN-8 (1-5 μM, 24 h) disrupts the structural integrity of 3D tumor spheres and reduces the number of live cells while increasing the proportion of dead cells in 3D spheres^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.